LA
PKBO

Linden Advisors’s Peak Bio, Inc. Common Stock PKBO Stock Holding History

Linden Advisors’s Portfolio PKBO Stock Details PKBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-121,857
Closed -$1.18M – 927
2021
Q1 		$1.18M Buy
+121,857
New +$1.18M 0.01% 495

Other funds holding PKBO

KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Linden Advisors's PKBO Position: Q2 2021 in Review

Linden Advisors sold out of Peak Bio, Inc. Common Stock (PKBO) in Q2 2021, closing a stake of 121,857 shares — an estimated $1.18M sold.

Linden Advisors first reported a position in PKBO in Q1 2021 and held it in 1 quarter. The position peaked at $1.18M in Q1 2021. 24 funds tracked by Wall St. Rank hold PKBO as of Q2 2021.

  • Linden Advisors reported no remaining Peak Bio, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Linden Advisors sold 121,857 Peak Bio, Inc. Common Stock shares in Q2 2021, an estimated $1.18M.
  • Linden Advisors first reported a position in Peak Bio, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Linden Advisors's Peak Bio, Inc. Common Stock position peaked at $1.18M in Q1 2021.
  • 24 funds tracked by Wall St. Rank held Peak Bio, Inc. Common Stock as of Q2 2021.

Based on Linden Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.